Biosimilars Regulatory Roundup for November 2022—Podcast Edition
Season 5 Episode 12 · Dec 04, 2022, 12:00 PM
Share
Subscribe
On this episode of Not So Different, we recap some of the big regulatory news to come out of November, including some progress for insulin biosimilars, the European approval of another ranibizumab biosimilar, and the congressional introduction of a US Senate bill that is seeking to nix switching study requirements for interchangeability.
Show notes
Rezvoglar Becomes Second Interchangeable Insulin Biosimilar
Biosimilar Business Recap: Progress for Insulin in Europe, Canada; Biocon Biologics' Viatris Acquisition Completed
The European Union Gains Another Ranibizumab Biosimilar
Alvotech Snags Australian Approval for Adalimumab Biosimilar
Biosimilar Check-in: PBM to Cover Adalimumab Biosimilars; World’s First Denosumab Biosimilar; Organon Launches in Canada
Senator Introduces Bill to Rid Switching Study Requirements for Interchangeability
BioRationality: A Dr Sarfaraz Niazi Column—FDA Launches Biosimilar Regulatory Science Program
AAM's Craig Burton: Is the Biden Administration Doing Enough to Help Biosimilars?
Rezvoglar Becomes Second Interchangeable Insulin Biosimilar
Biosimilar Business Recap: Progress for Insulin in Europe, Canada; Biocon Biologics' Viatris Acquisition Completed
The European Union Gains Another Ranibizumab Biosimilar
Alvotech Snags Australian Approval for Adalimumab Biosimilar
Biosimilar Check-in: PBM to Cover Adalimumab Biosimilars; World’s First Denosumab Biosimilar; Organon Launches in Canada
Senator Introduces Bill to Rid Switching Study Requirements for Interchangeability
BioRationality: A Dr Sarfaraz Niazi Column—FDA Launches Biosimilar Regulatory Science Program
AAM's Craig Burton: Is the Biden Administration Doing Enough to Help Biosimilars?